Navigation Links
Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
Date:4/7/2009

DENVER, April 7 /PRNewswire/ -- Pharmatech Oncology, Inc., a Research Management Organization (RMO), has been selected as one of the presenting companies at the Company Showcase during BIOZONA 2009 - Arizona's Annual Bioscience Industry Conference at the Sheraton Phoenix Downtown on April 7th in Phoenix, Arizona.

Matthew B. Wiener, PharmD, COO and Founder of Pharmatech Oncology, will present during the first session of the conference. The presentation will cover topics including: the science, business and markets on which the company is based, recent accomplishments, and strategic partnerships.

Dr. Wiener will focus on the many accomplishments for Pharmatech Oncology in cancer clinical trials utilizing the Just-In-Time (JIT) enrollment methodology. The aim of the Just-In-Time program is to shorten the time to enroll cancer patients into clinical trials and also expand the number of patients being offered trials. "Pharmatech Oncology is honored to be selected from a large number of applicants to be one of eighteen companies presenting at this distinguished BIOZONA event. We anticipate great exposure for our Just-In-Time clinical trial program, as we feel it is revolutionizing the enrollment process of adult cancer patients into clinical trials," states Dr. Wiener. For further information about BIOZONA 2009, please visit the event web site at http://www.azbio.org/Biozona2009.asp.

About Pharmatech Oncology:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. With Data Management as a separate business entity, it allows for management of data for other types of research aside from strictly oncology. Through an organized research network, the Company focuses on the development and utilization of therapeutic products among sponsors, investigators, and patients. For more information about Pharmatech Oncology, please visit www.pharmatechoncology.com.

Key Words: Oncology, Clinical Trials, Cancer, Patients, Contract Research, Site Management, Data Management, Research, Network, Just-In-Time, BIOZONA


'/>"/>
SOURCE Pharmatech Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
2. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
3. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
4. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
5. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
6. WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
7. Pharmatech 2.0: Introducing Pharmatech Oncology
8. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
9. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
10. WuXi PharmaTech Announces Third Quarter 2008 Results
11. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking ... initiative announced today. The bold new look is part of a transformation to ... into a significant growth period. , It will also expand its service offering from ...
(Date:10/10/2017)... firm Parks Associates announced today that Tom Kerber , ... Meeting , October 11 in Scottsdale, Arizona . Kerber ... smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
(Date:10/9/2017)... San Antonio, Texas (PRWEB) , ... ... ... a new study published on October 5, 2017, in the medical journal, ... demonstrated equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic ...
Breaking Biology Technology:
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed Anwar ... prestigious international IAIR Award for the most innovative high security ePassport and ... ... Maldives Immigration Controller General, Mr. Mohamed ... the right) have received the IAIR award for the "Most innovative high ...
Breaking Biology News(10 mins):